Literature DB >> 25625310

Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

Martina Kluth1, Rami Galal1, Antje Krohn1, Joachim Weischenfeldt2, Christina Tsourlakis1, Lisa Paustian1, Ramin Ahrary1, Malik Ahmed1, Sekander Scherzai1, Anne Meyer1, Hüseyin Sirma1, Jan Korbel2, Guido Sauter1, Thorsten Schlomm3, Ronald Simon1, Sarah Minner1.   

Abstract

Prostate cancer is characterized by structural rearrangements, most frequently including translocations between androgen-dependent genes and members of the ETS family of transcription factor like TMPRSS2:ERG. In a recent whole genome sequencing study we identified 140 gene fusions that were unrelated to ETS genes in 11 prostate cancers. The aim of the present study was to estimate the prevalence of non-ETS gene fusions. We randomly selected 27 of these rearrangements and analyzed them by fluorescence in situ hybridization (FISH) in a tissue microarray format containing 500 prostate cancers. Using break-apart FISH probes for one fusion partner each, we found rearrangements of 13 (48%) of the 27 analyzed genes in 300-400 analyzable cancers per gene. Recurrent breakage, often accompanied by partial deletion of the genes, was found for NCKAP5, SH3BGR and TTC3 in 3 (0.8%) tumors each, as well as for ARNTL2 and ENOX1 in 2 (0.5%) cancers each. One rearranged tumor sample was observed for each of VCL, ZNF578, IMMP2L, SLC16A12, PANK1, GPHN, LRP1 and ZHX2. Balanced rearrangements, indicating possible gene fusion, were found for ZNF578, SH3BGR, LPR12 and ZHX2 in individual cancers only. The results of the present study confirm that rearrangements involving non-ETS genes occur in prostate cancer, but demonstrate that they are highly individual and typically non-recurrent.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25625310     DOI: 10.3892/ijo.2015.2855

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.

Authors:  Niedzica Camacho; Peter Van Loo; Sandra Edwards; Jonathan D Kay; Lucy Matthews; Kerstin Haase; Jeremy Clark; Nening Dennis; Sarah Thomas; Barbara Kremeyer; Jorge Zamora; Adam P Butler; Gunes Gundem; Sue Merson; Hayley Luxton; Steve Hawkins; Mohammed Ghori; Luke Marsden; Adam Lambert; Katalin Karaszi; Gill Pelvender; Charlie E Massie; Zsofia Kote-Jarai; Keiran Raine; David Jones; William J Howat; Steven Hazell; Naomi Livni; Cyril Fisher; Christopher Ogden; Pardeep Kumar; Alan Thompson; David Nicol; Erik Mayer; Tim Dudderidge; Yongwei Yu; Hongwei Zhang; Nimish C Shah; Vincent J Gnanapragasam; William Isaacs; Tapio Visakorpi; Freddie Hamdy; Dan Berney; Clare Verrill; Anne Y Warren; David C Wedge; Andrew G Lynch; Christopher S Foster; Yong Jie Lu; G Steven Bova; Hayley C Whitaker; Ultan McDermott; David E Neal; Rosalind Eeles; Colin S Cooper; Daniel S Brewer
Journal:  PLoS Genet       Date:  2017-09-25       Impact factor: 5.917

2.  Genome-Wide Survey for Microdeletions or -Duplications in 155 Patients with Lower Urinary Tract Obstructions (LUTO).

Authors:  Luca M Schierbaum; Sophia Schneider; Stefan Herms; Sugirthan Sivalingam; Julia Fabian; Heiko Reutter; Stefanie Weber; Waltraut M Merz; Marcin Tkaczyk; Monika Miklaszewska; Przemyslaw Sikora; Agnieszka Szmigielska; Grazyna Krzemien; Katarzyna Zachwieja; Maria Szczepanska; Katarzyna Taranta-Janusz; Pawel Kroll; Marcin Polok; Marcin Zaniew; Alina C Hilger
Journal:  Genes (Basel)       Date:  2021-09-20       Impact factor: 4.096

Review 3.  Overview of research on fusion genes in prostate cancer.

Authors:  Chunjiao Song; Huan Chen
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.